Prognostic factors for febrile neutropenia;Facteurs pronostiques des neutropénies fébriles

Bulletin du Cancer

Volumn 93, Issue 5, 2006, Pages 501-506

  Ray Coquard, Isabelle ^a   Borg, Christophe ^a   Bachelot, Thomas ^a   Fayette, Jérome ^a   Zufferey, Laura ^a   Guastalla, Jean Paul ^a   Ghesquière, Hervé ^a   Blay, Jean Yves ^a   Sebban, Catherine ^a   Marec Bérard, Perrine ^a   Biron, Pierre ^a  

^a CENTRE LÉON BÉRARD   (France)

Author keywords

Colony stimulating factor; Febrile neutropenia; Prognostic factor

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR; ANTIANEMIC AGENT; HEMOPOIETIC GROWTH FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; COST EFFECTIVENESS ANALYSIS; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; FEBRILE NEUTROPENIA; HUMAN; INCIDENCE; INFECTION RISK; MORBIDITY; MORTALITY; PATIENT CARE; PREVALENCE; PROGNOSIS; REVIEW; RISK FACTOR; TREATMENT OUTCOME; ANTIBIOTIC PROPHYLAXIS; CHEMICALLY INDUCED DISORDER; DISEASE PREDISPOSITION; FEVER; NEUTROPENIA;

ANTIBIOTIC PROPHYLAXIS; ANTINEOPLASTIC AGENTS; DISEASE SUSCEPTIBILITY; FEVER; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HEMATINICS; HEMATOPOIETIC CELL GROWTH FACTORS; HUMANS; NEUTROPENIA; PROGNOSIS;

EID: 33745297826     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Bodey GP. Infection in cancer patients: a continuing association. Am J Med 1986; 81: 11-26.
2. Pizzo PA, Hathorn JW, Hiemenz J, Browne M, Commers J, Cotton D, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986; 315: 552-8.
3. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG, Levine AS, Deisseroth AB, et al. Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. Am J Med 1979; 67: 194-200.
4. Pizzo PA, Meyers J, Freifeld AG. Infection in the cancer patient. In: De Vita VH, ed. Cancer: principles and practice of oncology, 4 ed. Philadelphia, PA: Lippincott-Raven, 1993: 2292-337.
5. Chabner BA. Antimitotic drugs. Cancer Chemother Biol Response Modif 1993; 14: 55-60.
6. Chrischilles E, Delgado DJ, Stolshek BS, Lawless G, Fridman M, Carter WB. Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin's lymphoma. Cancer Control 2002; 9: 203-11.
7. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004; 100: 228-37.
8. Lyman GH, Lyman CH, Dale DC, Crawford J. Risk models for the prediction of chemotherapy induced neutropenia (CIN) and its consequences: a systematic review and classification. Blood 2001; 98: 413b.
9. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 2003; 21: 4524-31.
10. Extermann M, Chen H, Cantor AB, Corcoran MB, Meyer J, Grendys E, et al. Predictors of tolerance to chemotherapy in older cancer patients: a prospective pilot study. Eur J Cancer 2002; 38: 1466-73.
11. Balducci L. The geriatric cancer patient: equal benefit from equal treatment. Cancer Control 2001; 8: 1-25.
12. Balducci L, Extermann M. Cancer and aging. An evolving panorama. Hematol Oncol Clin North Am 2000; 14: 1-16.
13. Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, et al. 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 2000; 18: 3558-85.
14. Choi CW, Sung HJ, Park KH, Yoon SY, Kim SJ, Oh SC, et al. Early lymphopenia as a risk factor for chemotherapy-induced febrile neutropenia. Am J Hematol 2003; 73: 263-6.
15. Blay JY, Chauvin F, Le Cesne A, Anglaret B, Bouhour D, Lasset C, et al. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol 1996; 14: 636-43.
16. Blay JY, Ray-Coquard I, Mermet C, Maugard C, Ravaud A, Malet M, et al. A multicentric prospective study of prognostic factors for febrile neutropenia after chemotherapy in general and cancer hospitals. J Clin Oncol 1997; 16: 56a.
17. Ray-Coquard I, Borg C, Bachelot T, Sebban C, Philip I, Clapisson G, et al. Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. Br J Cancer 2003; 88: 181-6.
18. Blay JY, Le Cesne A, Mermet C, Maugard C, Ravaud A, Chevreau C, et al. A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy. Blood 1998; 92: 405-10.
19. Ray-Coquard I, Le Cesne A, Rubio MT, Mermet J, Maugard C, Ravaud A, et al. Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. J Clin Oncol 1999; 17: 2840.
20. Ray-Coquard I, Ghesquiere H, Bachelot T, Borg C, Biron P, Sebban C, et al. Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas. Br J Cancer 2001; 85: 816-22.
21. Cosler LE, Calhoun EA, Agboola O, Lyman GH. Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy. Pharmacother 2004; 24: 488-94.
22. Lyman GH, Kuderer N, Agboola O, Balducci L. Evidence-based use of colony-stimulating factors in elderly cancer patients. Cancer Control 2003; 10: 487-99.
23. Miser JS, Kinsella TJ, Triche TJ, Tsokos M, Jarosinski P, Forquer R, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 1987; 5: 1191-8.
24. Nichols CR, Williams SD, Loehrer PJ, Greco FA, Crawford ED, Weetlaufer J, et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 1991; 9: 1163-72.
25. Tannock IF, Boyd NF, DeBoer G, Erlichman C, Fine S, Larocque G, et al. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 1988; 6: 1377-87.
26. Asco. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1994; 12: 2471-508.
27. Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 2003; 98: 2402-9.
28. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328-40.
29. Viot M, Blanc-Vincent MP, Beal J, Biron P, Boutard P, Malgrange VB, et al. Infection and cancer: general information and specific questions. Presse Med 2000; 29: 1630-3.
30. Lyman GH, Lyman CG, Sanderson RA, Balducci L. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst 1993; 85: 488-93.
31. Lyman GH, Kuderer N, Greene J, Balducci L. The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer 1998; 34: 1857-64.
32. Donnelly JP. Selective decontamination of the digestive tract and its role in antimicrobial prophylaxis. J Antimicrob Chemother 1993; 31: 813-29.
33. Yoshida M, Ohno R. Antimicrobial prophylaxis in febrile neutropenia. Clin Infect Dis 2004; 39 (suppl. 1): S65-7.
34. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325: 164-70.
35. Clark OA, Lyman G, Castto AA, Clark LG, Djulbegovic B. Colony stimulating factors for chemotherapy induced febrile neutropenia. Cochrane Database Syst Rev 2003; CD003039.
36. Bohlius J, Reiser M, Schwarzer G, Engert A. Impact of granulocyte colony-stimulating factor (C-SF) and granulocyte-macrophage CSF in patients with malignant lymphoma: a systematic review. Br J Haematol 2003; 122: 413-23.
37. Berghmans T, Paesmans M, Lafitte JJ, Mascaux C, Meert AP, Jacquy C, et al. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis. Support Care Cancer 2002; 10: 181-8.
38. Hartmann LC, Tschetter LK, Habermann TM, Ebbert LP, Johnson PS, Mailliard JA, et al. Granulocyte colony-stimulating factor in severe chemotherapy-induced a febrile neutropenia. N Engl J Med 1997; 336: 1776-80.
39. Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med 2002; 112: 406-11.
40. Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003; 14: 29-35.
41. Vose JM, Crump M, Lazarus H, Emmanouilides C, Schenkein D, Moore J, et al. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 2003; 21: 514-9.
42. Sung L, Nathan PC, Lange B, Beyene J, Buchanan GR. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials. J Clin Oncol 2004; 22: 3350-6.
43. Blay JY, Le Cesne A, Blanc-Vincent MP, Fervers B, Latour JF, Philip T. Standards, options, and recommendations for the use of hematopoietic growth factors in oncology. Presse Med 2000; 29: 2004-8.